BXP Stock Overview
Manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Beximco Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳0.34 |
| 52 Week High | ৳0.44 |
| 52 Week Low | ৳0.19 |
| Beta | 0.62 |
| 11 Month Change | 15.52% |
| 3 Month Change | 15.52% |
| 1 Year Change | -21.18% |
| 33 Year Change | -67.79% |
| 5 Year Change | -19.01% |
| Change since IPO | 66.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 8.1% | 5.0% | 1.7% |
| 1Y | -21.2% | 2.2% | 8.3% |
Return vs Industry: BXP underperformed the UK Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: BXP underperformed the UK Market which returned 8% over the past year.
Price Volatility
| BXP volatility | |
|---|---|
| BXP Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BXP's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: BXP's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 1,122 | Iqbal Ahmed | www.beximcopharma.com |
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids.
Beximco Pharmaceuticals Limited Fundamentals Summary
| BXP fundamental statistics | |
|---|---|
| Market cap | UK£240.01m |
| Earnings (TTM) | UK£39.62m |
| Revenue (TTM) | UK£298.90m |
6.1x
P/E Ratio0.8x
P/S RatioIs BXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXP income statement (TTM) | |
|---|---|
| Revenue | ৳44.95b |
| Cost of Revenue | ৳25.04b |
| Gross Profit | ৳19.91b |
| Other Expenses | ৳13.95b |
| Earnings | ৳5.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.35 |
| Gross Margin | 44.29% |
| Net Profit Margin | 13.25% |
| Debt/Equity Ratio | 8.4% |
How did BXP perform over the long term?
See historical performance and comparison